Investigation of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in hemodialysis patients

輝美, 樋口; 由美子, 石川; 俊男, 山崎; 真理, 水野; 恵里奈, 大川; 晴美, 瀬戸口; 順子, 柳沢; 美佳, 吉沢; 那美, 堀之内; 美恵, 遊佐; 美幸, 早瀬; 英之, 安藤

doi:10.4009/jsdt.46.641

Nihon Toseki Igakkai Zasshi

2013

DOI: 10.4009/jsdt.46.641

|View full text |Cite

Investigation of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in hemodialysis patients

樋口輝美¹,

石川由美子²,

山崎俊男³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

非閉塞性腸管虚血を発症した透析患者の臨床的特徴の検討

Takano¹,

Hirai²,

Hara³

et al. 2023

Nihon Toseki Igakkai Zasshi

View full text Add to dashboard Cite

キーワード：非閉塞性腸管虚血，エリスロポエチン，エリスロポエチン抵抗性，動脈硬化，体液量 〈要旨〉 透析患者では，非閉塞性腸管虚血(NOMI)の発症頻度が高く予後不良である．NOMI の発症には直接的な誘因が不明な場合も多い．これらの患者の臨床的特徴を明らかにし発症との関連を検討した．NOMI を発症した 19 例を，直接的な誘因(心臓手術，心原性・出血性ショック)がある A 群(9 例)と，不明の B 群(10 例)に分けた．B 群では APACHEⅡスコアが低値であったが，動脈硬化性疾患の既往が多い傾向にあり，死亡率は同等であった (A 群； 77.8％，B 群；60％，p ＝0.63) ．また，エリスロポエチン(ESAs)使用量が多く(7,000 vs 3,000 U/週，p ＝0.015) ，エリスロポエチン抵抗性指数も高い傾向にあった (12.9 vs 4.3 U/kg/g/dL， p＝0.058) ．さらに，発症時の体重減少，ヘマトクリットの上昇傾向がみられた．直接的な誘因がない NOMI 症例でも死亡率は高く，組織低灌流の素地に加え，動脈硬化のみならず ESAs 投与量や抵抗性，循環血漿量減少および血液粘度上昇による腸管膜血流低下が NOMI 発症に関与する可能性が推察された．

show abstract

非閉塞性腸管虚血を発症した透析患者の臨床的特徴の検討

Takano¹,

Hirai²,

Hara³

et al. 2023

Nihon Toseki Igakkai Zasshi

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Investigation of hyporesponsiveness to erythropoiesis-stimulating agents (ESAs) in hemodialysis patients

Cited by 1 publication

References 29 publications

非閉塞性腸管虚血を発症した透析患者の臨床的特徴の検討

非閉塞性腸管虚血を発症した透析患者の臨床的特徴の検討

Contact Info

Product

Resources

About